Biotech Is Hot And Oncomed Pharmaceuticals Inc. (NASDAQ:OMED) Is Benefiting
Healthcare is hot right now, and there’s no hotter space from a fund perspective than oncology. Here’s a look at the Vertical Fund’s latest equity acquisition, a position taken in small cap cancer focus biotech, Oncomed.
In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Oncomed Pharmaceuticals Inc. (NASDAQ:OMED) reported that Vertical Fund I Lp has picked up 1,119,905 of common stock as of 2017-01-13.
The acquisition brings the aggregate amount owned by Vertical Fund I Lp to a total of 1,119,905 representing a 3.0% stake in the company.
For those not familiar with the company, OncoMed Pharmaceuticals, Inc. (OncoMed) is a clinical development-stage biopharmaceutical company. The Company focuses on discovering and developing anti-cancer stem cell (CSC) and immuno-oncology therapeutics. The Company’s product candidates and preclinical programs include Demcizumab (Anti-DLL4, OMP-21M18), Tarextumab (Anti-Notch2/3, OMP-59R5), Vantictumab (anti-Fzd7, OMP-18R5), Ipafricept (Fzd8-Fc, OMP-54F28), Brontictuzumab (Anti-Notch1, OMP-52M51), Anti-DLL4/VEGF Bispecific (OMP-305B83), Anti-RSPO3 (OMP-131R10) and GITRL-Fc. The Company’s Demcizumab is a humanized monoclonal antibody that inhibits Delta-like Ligand 4 (DLL4), in the Notch signaling pathway. Tarextumab is an antibody that binds to both the Notch2 and Notch3 receptors. Ipafricept is the Company’s Wnt pathway modulator. GITRL-Fc is a preclinical product candidate targeting glucocorticoid-induced tumor necrosis factor receptor related protein.
A glance at Oncomed Pharmaceuticals Inc. (NASDAQ:OMED)’s key stats reveals a current market capitalization of 277.08 million based on 37.09 million shares outstanding and a price at last close of $8.02 per share.
Looking at insider activity, there are a few transactions worth noting.
Specifically, on 2015-09-30, Lasersohn picked up 9,120 at a purchase price of $16.26. This brings their total holding to 46,560 as of the date of the filing.
On the sell side, the most recent transaction saw Park unload 21,369 shares at a sale price of $8.52. This brings their total holding to 37,323.
It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Oncomed Pharmaceuticals Inc. (NASDAQ:OMED) as things move forward to see if its progress aligns with these transactions.
Subscribe below and we’ll keep you on top of what’s happening before it moves markets.
Sunesis Pharmaceuticals Inc. (NASDAQ:SNSS) Is Attracting Smart Money
Palo Alto has been busy in the healthcare sector over the last couple of days. Here’s a look at the fund’s second healthcare filing of the day, and what it means for the company involved.
In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Sunesis Pharmaceuticals Inc. (NASDAQ:SNSS) reported that Palo Alto Investors has picked up 1,162,473 of common stock as of 2017-01-13.
The acquisition brings the aggregate amount owned by Palo Alto Investors to a total of 1,162,473 representing a 5.57% stake in the company.
For those not familiar with the company, Sunesis Pharmaceuticals, Inc. is a biopharmaceutical company. The Company focuses on the development and commercialization of its pipeline of oncology therapeutics for the treatment of solid and hematologic cancers. The Company offers QINPREZO (vosaroxin), which is a product candidate for the treatment of acute myeloid leukemia (AML). Vosaroxin is an anticancer quinolone derivative (AQD). The Company’s other kinase inhibitor pipeline include TAK-580, SNS-062 and SNS-229. TAK-580 is an oral, investigative drug selective for pan-Raf kinase inhibition, in patients with relapsed or refractory solid tumors. SNS-062 is a non-covalently binding inhibitor of Bruton’s tyrosine kinase (BTK).
A glance at Sunesis Pharmaceuticals Inc. (NASDAQ:SNSS)’s key stats reveals a current market capitalization of 80.60 million based on 20.88 million shares outstanding and a price at last close of $3.88 per share.
Looking at insider activity, there are a few transactions worth noting.
Specifically, on 2016-12-09, Parker picked up 594 at a purchase price of $3.90. This brings their total holding to 14,074 as of the date of the filing.
On the sell side, the most recent transaction saw Misfeldt unload 3,962 shares at a sale price of $3.64. This brings their total holding to 105,134.
It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Sunesis Pharmaceuticals Inc. (NASDAQ:SNSS) as things move forward to see if its progress aligns with these transactions.
Subscribe below and we’ll keep you on top of what’s happening before it moves markets.
Here’s Who Just Picked Up Rhino Resource Partners Lp (OTCMKTS:RHNO) Shares
In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Rhino Resource Partners Lp (OTCMKTS:RHNO) reported that Royal Energy Resources, Inc. has picked up 8,363,229 of common stock as of 2017-01-13.
The acquisition brings the aggregate amount owned by Royal Energy Resources, Inc. to a total of 8,363,229 representing a 44.4% stake in the company.
For those not familiar with the company, Rhino Resource Partners LP is an energy limited partnership that is focused on coal and energy related assets and activities, including energy infrastructure investments. The Company produces, processes and sells coal of various steam and metallurgical grades from multiple coal producing basins in the United States. It operates through four segments. The Central Appalachia segment consists of over two mining complexes: Tug River and Rob Fork. The Northern Appalachia segment consists of the Hopedale mining complex, the Sands Hill mining complex and the Leesville field. The Rhino Western segment includes its underground mine in the Western Bituminous region.
A glance at Rhino Resource Partners Lp (OTCMKTS:RHNO)’s key stats reveals a current market capitalization of 38.94 million based on 7.91 million shares outstanding and a price at last close of $4.26 per share.
Looking at insider activity, there are a few transactions worth noting.
Specifically, on 2016-09-27, Tuorto picked up 500 at a purchase price of $2.20. This brings their total holding to 86,621 as of the date of the filing.
On the sell side, the most recent transaction saw Morris unload 3,739 shares at a sale price of $4.50. This brings their total holding to 1,950.
It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Rhino Resource Partners Lp (OTCMKTS:RHNO) as things move forward to see if its progress aligns with these transactions.
Subscribe below and we’ll keep you on top of what’s happening before it moves markets.
Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Just Announced A Big Name Backer
With JP Morgan out of the way, it’s time for the biotechnology space to return to normality. Well, normality, that is, as far as the biotech space can be normal. There remains a host of catalysts and data drops on the calendar, and these have the potential to drive volume. Here’s the latest acquisition ahead of these catalysts hitting press.
In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) reported that Palo Alto Investors has picked up 4,203,270 of common stock as of 2017-01-13.
The acquisition brings the aggregate amount owned by Palo Alto Investors to a total of 4,203,270 representing a 9.56% stake in the company.
For those not familiar with the company, Vanda Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of pharmaceutical products for the treatment of central nervous system (CNS) disorders. The Company’s product portfolio includes HETLIOZ (tasimelteon), Fanapt (iloperidone), Tradipitant (VLY-686), Trichostatin A and AQW051. The Company offers HETLIOZ (tasimelteon) for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24). The Company offers Fanapt (iloperidone) for the treatment of schizophrenia. Additionally, its distribution partners launched Fanapt in Israel and Mexico. Tradipitant (VLY-686) is a small molecule neurokinin-1 receptor (NK-1R) antagonist, which is in clinical development for the treatment of chronic pruritus in atopic dermatitis.
A glance at Vanda Pharmaceuticals Inc. (NASDAQ:VNDA)’s key stats reveals a current market capitalization of 584.08 million based on 43.95 million shares outstanding and a price at last close of $14.05 per share.
Looking at insider activity, there are a few transactions worth noting.
Specifically, on 2015-12-16, Flynn picked up 3,239 at a purchase price of $8.97. This brings their total holding to 1,103,617 as of the date of the filing.
On the sell side, the most recent transaction saw Baroldi unload 16,300 shares at a sale price of $15.51. This brings their total holding to 54,365.
It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) as things move forward to see if its progress aligns with these transactions.
Subscribe below and we’ll keep you on top of what’s happening before it moves markets.